Rsgk.Jk

RSGK.JK maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.18, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.0, suggesting that it has just enough current assets to cover its current liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk.

In terms of profitability, RSGK.JK reports a return on equity (ROE) of 4.16% and a return on assets (ROA) of 3.18%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of generating returns on equity and assets.

The company's revenue is primarily concentrated in the pharmaceuticals and healthcare services segments, with no significant geographic diversification disclosed in the available data. This concentration could expose the company to specific market risks if demand in these segments declines.

RSGK.JK's growth trajectory is not explicitly detailed in the available data, but the company's operating income and net income figures suggest a stable performance. The company's capital expenditure is negative, indicating that it is not investing in new assets, which could affect its long-term growth potential.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully to avoid liquidity issues. There is no mention of recent significant events or filings that would impact the company's operations or financial position.